Full Program Just Released!
Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Yu-Shin Hsu

Yu-Shin Hsu

Senior Research Analyst Beacon

Seminars

Monday 12th October 2026

Deep Diving Into the Next Wave of Bioconjugate Design & Mechanisms to Overcome Payload Resistance & Enhance ADC Therapeutic Properties

9:30 am

Breaking down the exciting landscape of novel drug conjugate design and mechanisms of action
Exploring emerging trends across conjugate design and targets
Spotlighting novel conjugate innovation across multi payload ADCs, bispecific ADCs and degrader antibody conjugates

_Yu-Shin Hsu - Speaker at 17th World ADC San Diego Summit

View all Speakers

View Event Brochure